Skip to main content
David Staskin, MD, Urology, Boston, MA, St. Elizabeth's Medical Center

DavidR.StaskinMD

Urology • Boston, MA

Female Urology/Pelvic Medicine & Reconstructive Surgery

Associate Professor, Urology, Tufts University School of Medicine

Join to view full profile

Dr. Staskin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Staskin's full profile

Already have an account?

Education & Training

  • Ronald Reagan UCLA Medical Center
    Ronald Reagan UCLA Medical CenterUrology, 1984 - 1985
  • University of Pennsylvania Health System
    University of Pennsylvania Health SystemResidency, Urology, 1980 - 1984
  • University of California (San Diego) Medical Center
    University of California (San Diego) Medical CenterInternship, Transitional Year, 1979 - 1980
  • Drexel University College of Medicine
    Drexel University College of MedicineClass of 1979

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 1985 - 2025
  • NY State Medical License
    NY State Medical License 2002 - 2010
  • American Board of Urology Urology

Awards, Honors, & Recognition

  • Boston Magazine Castle Connolly, 2013
  • CMS Meaningful Use Stage 1 Certification eClinicalWorks EHR, eClinicalWorks LLC, 2012-2013
  • Top Doctors: New York Metro Area Castle Connolly, 2005-2009
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • Urovant Sciences Presents New Data from EMPOWUR Study, Advancing Knowledge of the Treatment of Overactive Bladder at the 2022 American Urological Association Meeting
    Urovant Sciences Presents New Data from EMPOWUR Study, Advancing Knowledge of the Treatment of Overactive Bladder at the 2022 American Urological Association MeetingMay 16th, 2022
  • Urovant Sciences to Present Interim Data from Phase 2a Study of Potential Novel Gene Therapy, URO-902, and New Analyses of Data from Phase 3 EMPOWUR Extension Trial of GEMTESA® (Vibegron) 75 Mg at 2022 American Urological Association Annual Meeting
    Urovant Sciences to Present Interim Data from Phase 2a Study of Potential Novel Gene Therapy, URO-902, and New Analyses of Data from Phase 3 EMPOWUR Extension Trial of GEMTESA® (Vibegron) 75 Mg at 2022 American Urological Association Annual MeetingApril 13th, 2022
  • Urovant Sciences Presents Positive Ambulatory Blood Pressure Data Showing That GEMTESA® (Vibegron) 75 Mg in Overactive Bladder Was Not Associated with Statistically Significant or Clinically Meaningful Effects on Blood Pressure or Heart Rate
    Urovant Sciences Presents Positive Ambulatory Blood Pressure Data Showing That GEMTESA® (Vibegron) 75 Mg in Overactive Bladder Was Not Associated with Statistically Significant or Clinically Meaningful Effects on Blood Pressure or Heart RateSeptember 13th, 2021
  • Join now to see all

Hospital Affiliations

Dr. David Staskin, Dr. David Staskin, MD, Dr. D Staskin, Dr. David R. Staskin